Literature DB >> 24829361

Renal nerve ablation after SYMPLICITY HTN-3: confused at the higher level?

Thomas F Lüscher1, Felix Mahfoud2.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24829361      PMCID： PMC5994825          DOI： 10.1093/eurheartj/ehu195

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  25 in total

1.  2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension.

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stephane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad
Journal:  Blood Press       Date:  2013-12-20       Impact factor: 2.835

2.  Catheter-based renal denervation: the black box procedure.

Authors:  Felix Mahfoud; Deepak L Bhatt
Journal:  JACC Cardiovasc Interv       Date:  2013-10       Impact factor: 11.195

3.  Expert consensus document from the European Society of Cardiology on catheter-based renal denervation.

Authors:  Felix Mahfoud; Thomas Felix Lüscher; Bert Andersson; Iris Baumgartner; Renata Cifkova; Carlo Dimario; Pieter Doevendans; Robert Fagard; Jean Fajadet; Michel Komajda; Thierry Lefèvre; Chaim Lotan; Horst Sievert; Massimo Volpe; Petr Widimsky; William Wijns; Bryan Williams; Stephan Windecker; Adam Witkowski; Thomas Zeller; Michael Böhm
Journal:  Eur Heart J       Date:  2013-04-25       Impact factor: 29.983

4.  Cardiovascular disease in Europe: epidemiological update.

Authors:  Melanie Nichols; Nick Townsend; Peter Scarborough; Mike Rayner
Journal:  Eur Heart J       Date:  2013-09-07       Impact factor: 29.983

5.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

6.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

7.  Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study.

Authors:  Henry Krum; Markus P Schlaich; Paul A Sobotka; Michael Böhm; Felix Mahfoud; Krishna Rocha-Singh; Richard Katholi; Murray D Esler
Journal:  Lancet       Date:  2013-11-07       Impact factor: 79.321

8.  Risk stratification by ambulatory blood pressure monitoring across JNC classes of conventional blood pressure.

Authors:  Jana Brguljan-Hitij; Lutgarde Thijs; Yan Li; Tine W Hansen; Jose Boggia; Yan-Ping Liu; Kei Asayama; Fang-Fei Wei; Kristina Bjorklund-Bodegard; Yu-Mei Gu; Takayoshi Ohkubo; Jorgen Jeppesen; Christian Torp-Pedersen; Eamon Dolan; Tatiana Kuznetsova; Stolarz-Skrzypek Katarzyna; Valerie Tikhonoff; Sofia Malyutina; Edoardo Casiglia; Yuri Nikitin; Lars Lind; Edgardo Sandoya; Kalina Kawecka-Jaszcz; Jan Filipovsky; Yutaka Imai; Jiguang Wang; Eoin O'Brien; Jan A Staessen
Journal:  Am J Hypertens       Date:  2014-02-26       Impact factor: 2.689

9.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

10.  Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension.

Authors:  Felix Mahfoud; Christian Ukena; Roland E Schmieder; Bodo Cremers; Lars C Rump; Oliver Vonend; Joachim Weil; Martin Schmidt; Uta C Hoppe; Thomas Zeller; Axel Bauer; Christian Ott; Erwin Blessing; Paul A Sobotka; Henry Krum; Markus Schlaich; Murray Esler; Michael Böhm
Journal:  Circulation       Date:  2013-06-18       Impact factor: 29.690
View more
  20 in total

1.  Renal denervation attenuates progression of atherosclerosis in apolipoprotein E-deficient mice independent of blood pressure lowering.

Authors:  Hui Wang; Jintao Wang; Chiao Guo; Wei Luo; Kyle Kleiman; Daniel T Eitzman
Journal:  Hypertension       Date:  2015-02-02       Impact factor: 10.190

Review 2.  Renal Denervation After Symplicity HTN-3 - Back to Basics. Review of the Evidence.

Authors:  Alexandre Persu; Fadl Elmula M Fadl Elmula; Yu Jin; Ingrid Os; Sverre E Kjeldsen; Jan A Staessen
Journal:  Eur Cardiol       Date:  2014-12

3.  Effects of renal denervation on 24-h heart rate and heart rate variability in resistant hypertension.

Authors:  Christian Ukena; Tobias Seidel; Konstantinos Rizas; Davide Scarsi; Dominic Millenaar; Sebastian Ewen; Axel Bauer; Felix Mahfoud; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2019-09-25       Impact factor: 5.460

4.  Procedural and Anatomical Determinants of Multielectrode Renal Denervation Efficacy.

Authors:  Abraham R Tzafriri; Felix Mahfoud; John H Keating; Anna-Maria Spognardi; Peter M Markham; Gee Wong; Debby Highsmith; Patrick O'Fallon; Kristine Fuimaono; Elazer R Edelman
Journal:  Hypertension       Date:  2019-07-15       Impact factor: 10.190

Review 5.  Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges.

Authors:  Alexandre Persu; Sverre Kjeldsen; Jan A Staessen; Michel Azizi
Journal:  Curr Hypertens Rep       Date:  2016-01       Impact factor: 5.369

6.  Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry.

Authors:  Christian Ukena; Felix Mahfoud; Sebastian Ewen; Andreas Bollmann; Gerhard Hindricks; Boris A Hoffmann; Dominik Linz; Dan Musat; Valerie Pavlicek; Eberhard Scholz; Dierk Thomas; Stephan Willems; Michael Böhm; Jonathan S Steinberg
Journal:  Clin Res Cardiol       Date:  2016-06-30       Impact factor: 5.460

7.  Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis.

Authors:  Sebastian Ewen; Markus R Meyer; Bodo Cremers; Ulrich Laufs; Andreas G Helfer; Dominik Linz; Ingrid Kindermann; Christian Ukena; Michel Burnier; Stefan Wagenpfeil; Hans H Maurer; Michael Böhm; Felix Mahfoud
Journal:  Clin Res Cardiol       Date:  2015-08-26       Impact factor: 5.460

8.  Renal nerve ablation reduces blood pressure in resistant hypertension: Long-term clinical outcomes in a single-center experience.

Authors:  Andrea Denegri; Tino Naduvathumuriyil; Thomas Felix Lüscher; Isabella Sudano
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-03-25       Impact factor: 3.738

9.  Finding the best ablation strategy for renal denervation: A continuing saga.

Authors:  Kyriakos Dimitriadis; Costas Tsioufis; Dimitrios Tousoulis
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-03-21       Impact factor: 3.738

Review 10.  Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in severe hypertension.

Authors:  Fadl Elmula M Fadl Elmula; Anne C Larstorp; Sverre E Kjeldsen; Alexandre Persu; Yu Jin; Jan A Staessen
Journal:  Front Physiol       Date:  2015-02-09       Impact factor: 4.566
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.